Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Curti

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
Cancer Research|November 2, 2013
OX40 is a potent immune-stimulating target in late-stage cancer patientsBrendan D Curti, Magdalena Kovacsovics-Bankowski, Nicholas Morris, et al.
Frontiers in Immunology|September 24, 2024
Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipientsCraig P Collins, Lam T Khuat, Gail D Sckisel, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
Current Molecular Medicine|August 20, 2009
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effectsUlf Petrausch, Christian H Poehlein, Shawn M Jensen, et al.
JAMA Network Open|January 28, 2026
Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung CancerChiharu Sako, Brenda F Kurland, Taly G Schmidt, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Journal of the National Cancer Institute|January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanomaJ E Janik, L L Miller, D L Longo, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Cancer Discovery|May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinomaR G Fenton, R G Steis, K Madara, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
Cancer Research|November 2, 2013
OX40 is a potent immune-stimulating target in late-stage cancer patientsBrendan D Curti, Magdalena Kovacsovics-Bankowski, Nicholas Morris, et al.
Frontiers in Immunology|September 24, 2024
Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipientsCraig P Collins, Lam T Khuat, Gail D Sckisel, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
Current Molecular Medicine|August 20, 2009
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effectsUlf Petrausch, Christian H Poehlein, Shawn M Jensen, et al.
JAMA Network Open|January 28, 2026
Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung CancerChiharu Sako, Brenda F Kurland, Taly G Schmidt, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Journal of the National Cancer Institute|January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanomaJ E Janik, L L Miller, D L Longo, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Cancer Discovery|May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinomaR G Fenton, R G Steis, K Madara, et al.
Pageof 13